Arcus Biosciences, Inc. (RCUS): Free Cash Flow
-$484.00M
Year ended 2025-12-31
-$475.00M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$484.00M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$176.00M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$330.00M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $432.00M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$282.00M | n/m | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $108.00M | n/c | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$75.39M | n/m | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | -$46.74M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$30.57M | n/m | 2019-03-05, From 2017-01-01 |
| 2016-12-31 | -$17.04M | n/a | 2019-03-05, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$484.00M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $105.95M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $12.46M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $67.70M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $19.61M | n/m |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$275.70M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $41.73M | +7.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $48.91M | -48.6% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | -$24.61M | n/m |
Compare RCUS, KROS, SDGR, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗